Literature DB >> 1828522

Production of endothelin-1 from the mesenteric arteries of streptozotocin-induced diabetic rats.

Y Takeda1, I Miyamori, T Yoneda, R Takeda.   

Abstract

Release of endothelin-1 (ET-1) from the mesenteric arteries of Wistar rats with streptozotocin-induced diabetes (STZ-DM) rats and nondiabetic rats was measured by a specific enzyme immunoassay following purification using an immunoaffinity column. The mesenteric arteries from STZ-DM rats released a significantly higher amount of ET-1 as compared to control rats (35.8 +/- 2.8 vs 14.9 +/- 2.0 pg/1hr, p less than 0.05). The plasma level of ET-1 in STZ-DM rats was also elevated to a significant extent as compared to controls (5.1 +/- 0.4 vs 3.0 +/- 0.4 pg/ml, p less than 0.05). The systolic blood pressure of STZ-DM rats was significantly higher than of the controls (p less than 0.05). The increased level of plasma ET-1 as well as its release from the mesenteric artery of STZ-DM rats may suggest its release following damage to the endothelium caused by diabetes and/or by associated changes in blood pressure.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1828522     DOI: 10.1016/0024-3205(91)90611-e

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  10 in total

1.  Endothelin-1-mediated cerebrovascular remodeling is not associated with increased ischemic brain injury in diabetes.

Authors:  Weiguo Li; Aisha I Kelly-Cobbs; Erin M Mezzetti; Susan C Fagan; Adviye Ergul
Journal:  Can J Physiol Pharmacol       Date:  2010-08       Impact factor: 2.273

2.  Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1.

Authors:  Kamakshi Sachidanandam; Jim R Hutchinson; Mostafa M Elgebaly; Erin M Mezzetti; Anne M Dorrance; Kouros Motamed; Adviye Ergul
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-01-28       Impact factor: 3.619

3.  Vasoreactivity and prostacyclin release in streptozotocin-diabetic rats: effects of insulin or aldose reductase inhibition.

Authors:  E J Stevens; G B Willars; P Lidbury; F House; D R Tomlinson
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

4.  The potential contribution of endothelin-1 to neurovascular abnormalities in streptozotocin-diabetic rats.

Authors:  N E Cameron; K C Dines; M A Cotter
Journal:  Diabetologia       Date:  1994-12       Impact factor: 10.122

5.  The effects of 5-hydroxytryptamine 5-HT2 receptor antagonists on nerve conduction velocity and endoneurial perfusion in diabetic rats.

Authors:  Norman E Cameron; Mary A Cotter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-05-13       Impact factor: 3.000

6.  Endothelium-dependent inhibition of Na(+)-K+ ATPase activity in rabbit aorta by hyperglycemia. Possible role of endothelium-derived nitric oxide.

Authors:  S Gupta; I Sussman; C S McArthur; K Tornheim; R A Cohen; N B Ruderman
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

7.  Altered microvascular reactivity to endothelin-1, endothelin-3 and NG-nitro-L-arginine methyl ester in streptozotocin-induced diabetes mellitus.

Authors:  E Lawrence; S D Brain
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

8.  Effects of endothelin receptor antagonism with bosentan on peripheral nerve function in experimental diabetes.

Authors:  E J Stevens; D R Tomlinson
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

9.  Effects of evening primrose oil treatment on sciatic nerve blood flow and endoneurial oxygen tension in streptozotocin-diabetic rats.

Authors:  N E Cameron; M A Cotter
Journal:  Acta Diabetol       Date:  1994-12       Impact factor: 4.280

10.  Blockade of Endothelin-1 Receptor Type B Ameliorates Glucose Intolerance and Insulin Resistance in a Mouse Model of Obstructive Sleep Apnea.

Authors:  Jan Polak; Naresh M Punjabi; Larissa A Shimoda
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-29       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.